Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Elena Shagisultanova; William J. Gradishar; Ursa Brown-Glaberman; Pavani Chalasani; Andrew Brenner; Alison Stopeck; Hannah Parris; Dexiang Gao; Tessa McSpadden; José Mayordomo; Jennifer R. Diamond; Peter Kabos; Virginia F. Borges

doi:10.1158/1078-0432.30833948

Abstract

<p>Grade 3 and 4 AEs - palbociclib 125mg vs 75mg</p>

Related Publications

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

M. Pérol , Clarisse Audigier-Valette , Olivier Molinier +17 more

9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuatio...

2017 Journal of Clinical Oncology 6 citations

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

William J. Gradishar , Sergei Tjulandin , Neville Davidson +5 more

Purpose ABI-007, the first biologically interactive albumin-bound paclitaxel in a nanameter particle, free of solvents, was compared with polyethylated castor oil–based standard...

2005 Journal of Clinical Oncology 2071 citations

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu , Yoon‐Koo Kang , Chia‐Jui Yen +21 more

Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...

2019 The Lancet Oncology 1593 citations

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

J. D. Wolchok , L. Thomas , I. N. Bondarenko +7 more

LBA5 Background: IPI monotherapy (3mg/kg) improved overall survival (OS) in a phase III study of previously treated, unresectable or metastatic melanoma. Current study in 1st li...

2011 Journal of Clinical Oncology 13 citations

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael A. Morse , Eric Van Cutsem , Ray McDermott +17 more

Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previou...

2018 Journal of Clinical Oncology 1962 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Elena Shagisultanova, 
                                
                                    William J. Gradishar, 
                                
                                    Ursa Brown-Glaberman
                                
                                et al.
                            
                            (2025). 
                            Supplementary Fig. S2 from Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer. 
                            
                            .
                            https://doi.org/10.1158/1078-0432.30833948

Identifiers

DOI: 10.1158/1078-0432.30833948